

Zynex Announces Webinar to Address the US Opioid Epidemic

PR Newswire
LONE TREE, Colo.

LONE TREE, Colo., Nov 28, 2017 /PRNewswire/ -- **Zynex** (OTCQB: ZYXI) is an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics. The company continues to introduce several new products to its product portfolio in its efforts to address the pain and rehabilitation markets and the current opioid epidemic.

Zynex Opioid Epidemic Webinar.

The current Opioid Epidemic has been declared a health emergency and Zynex is uniquely positioned to help reduce the amount of opioids prescribed for treatment of chronic and acute pain symptoms. We are hosting a national webinar to reach more healthcare practitioners who are prescribing opioids and give them a true alternative pain relief choice over opioids. The Zynex product line, offers relief for chronic and acute pain without side-effects, the risk of addiction or death. The webinar will not only inform practitioners about the benefits our products, but will introduce them to our EZ-Prescribe program which makes prescribing our products faster and easier for practitioners and patients.

The webinar is scheduled for December 14, 2017 at 12:00 Eastern Time and will be available to anyone interested in learning more about how Zynex can help address the Opioid Epidemic Health Emergency.

See below webinar information:

<https://attendee.gotowebinar.com/register/8109804639454547715>

About Zynex

Zynex, founded in 1996, markets and sells its own design of electrotherapy medical devices used for pain management and rehabilitation; and the company's proprietary NeuroMove device designed to help recovery of stroke and spinal cord injury patients. Zynex is also developing a new blood volume monitor for use in hospitals and surgery centers. For additional information, please visit: Zynex.com.

Safe Harbor Statement

Certain statements in this release are "forward-looking" and as such are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain FDA clearance and CE marking of new products, the acceptance of new products as well as existing products by doctors and hospitals, larger competitors with greater financial resources, the need to keep pace with technological changes, our dependence on the reimbursement from insurance companies for products sold or rented to our customers, acceptance of our products by health insurance providers, our dependence on third party manufacturers to produce our goods on time and to our specifications, implementation of our sales strategy including a strong direct sales force our ability to up-list to a larger exchange and other risks described in our filings with the Securities and Exchange Commission including the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2016 as well as Forms 10-Q, 8-K and 8-K/A, press releases and the Company's website.

Contact:

Zynex, Inc.

(303) 703-4906

Investor Relations Contact:

Amato And Partners, LLC

Investor Relations Counsel

admin@amatoandpartners.com

View original content with multimedia:<http://www.prnewswire.com/news-releases/zynex-announces-webinar-to-address-the-us-opioid-epidemic-300562640.html>

SOURCE Zynex

<https://zynexmed.investorroom.com/2017-11-28-Zynex-Announces-Webinar-to-Address-the-US-Opioid-Epidemic>